The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $117.53

Today's change-2.75 -2.29%
Updated April 27 2:36 PM EDT. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $117.53

Today's change-2.75 -2.29%
Updated April 27 2:36 PM EDT. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc down (U.S.)$2.75

Biomarin Pharmaceutical Inc is sharply lower today, dropping (U.S.)$2.75 or 2.29% to (U.S.)$117.53. Shares have lost 2.16% over the last five days, but have gained 30.01% over the last year to date. This security has outperformed the S&P 500 by 92.44% during the last year.

Key company metrics

  • Open(U.S.) $120.72
  • Previous close(U.S.) $120.28
  • High(U.S.) $124.95
  • Low(U.S.) $116.18
  • Bid / Ask(U.S.) $117.43 / (U.S.) $117.52
  • YTD % change+30.01%
  • Volume1,980,423
  • Average volume (10-day)1,033,810
  • Average volume (1-month)1,455,205
  • Average volume (3-month)1,520,938
  • 52-week range(U.S.) $55.36 to (U.S.) $133.54
  • Beta0.83
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.92
Updated April 27 2:36 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-17.84%

Biomarin Pharmaceutical Inc has a net profit margin of -17.84%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.44%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue231177192152
Total other revenue--------
Total revenue231177192152
Gross profit185147161129
Total cost of revenue46303123
Total operating expense290166211178
Selling / general / administrative88796860
Research & development14212610886
Depreciation / amortization10111
Interest expense (income), net operating--------
Unusual expense (income)5-6810
Other operating expenses, total-13238
Operating income-5911-20-26
Interest income (expense), net non-operating-9-9-9-9
Gain (loss) on sale of assets--------
Other--------
Income before tax-663-28-35
Income after tax-707-34-38
Income tax, total4-463
Net income-707-34-38
Total adjustments to net income--------
Net income before extra. items-707-34-38
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-707-34-38
Inc. avail. to common incl. extra. items-707-34-38
Diluted net income-708-34-38
Dilution adjustment--000
Diluted weighted average shares148159146144
Diluted EPS excluding extraordinary itemsvalue per share-0.470.05-0.23-0.26
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.45-0.23-0.23-0.26